From the Vault: What unique challenges arise when building a disease model for NASH prevalence and what strategies do leading modelers use to overcome them?
In this final conversation the Surfers explore the impact they believe ICER’s draft report on resmetirom and obeticholic acid for NASH will have for different stakeholders. The panelists each touch on different perspectives to offer a well-rounded wrap-up.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group explores the pros and cons of biopsy while critiquing the report’s position on the practice. Discussion goes on to consider challenges for payers trying to determine the economic impacts of these drugs.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists discuss how to effectively collect and implement changes reflected by the explosion of data emerging from the NAFLD and NASH space.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, Hannah Mamuszka, founder and CEO of Alva10, discusses the report’s assessment of disease prevalence and outlines payer perspectives on prospective drug efficacy.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute, Veronica Miller of the Liver Forum and new guest, Hannah Mamuszka, who is founder and CEO of Alva10. This leading conversation provides an introduction to a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.
The Surfers evaluate a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This high-caliber session offers a plethora of practical considerations around accessing approved NASH pharmacotherapies for those most in need.
Jörn Schattenberg, Louise Campbell, Stephen Harrison and Roger Green share “SurfingNASH predictions” of the most important events that will take place between the 5th and 6th International NASH Days.
This final segment with Jeff McIntyre of the Global Liver Institute (GLI) wraps up discussion around what’s happening in NAFLD and NASH for the first quarter of an exciting year. Roger Green invites the panelists to provide the most significant and optimistic thing they will be touching over the next three months followed by the greatest fear each has in the same space.
